Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade	Last Price	% Change	Price Change
	14.37	3.83%	0.53

APLS closed up 3.83 percent on Tuesday, February 19, 2019, on 59 percent of normal volume.

ADX	Long-Term	Intermediate-Term	Short-Term
Weak or Absent	Down	Down	Up
See historical APLS trend table...

Date	Alert Name	Type	% Chg
Feb 19	Bollinger Band Squeeze	Range Contraction	0.00%
Feb 19	BB Squeeze Started	Range Contraction	0.00%
Feb 19	Overbought Stochastic	Strength	0.00%
Feb 15	20 DMA Support	Bullish	3.83%
Feb 15	Outside Day	Range Expansion	3.83%
Feb 14	Stochastic Reached Overbought	Strength	1.13%
Feb 14	Weak + Overbought	Other	1.13%
Feb 14	Overbought Stochastic	Strength	1.13%
Feb 12	Crossed Above 20 DMA	Bullish	0.00%
Feb 11	Fell Below 20 DMA	Bearish	4.74%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh

Indicator	Bull Case	Neutral / Hold	Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary:	Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Date	Title
Feb 12	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 11	FDA grants Fast Track designation to Apellis Pharma's APL-2
Feb 11	Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
Feb 5	Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
Jan 31	Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
Jan 23	UBS likes Lilly in premarket analyst action
Jan 14	Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
Jan 9	Apellis Pharmaceuticals (APLS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
Jan 2	Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 30	Planned equity offering roundup - healthcare

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					15.53
Resistance 3 (R3)	15.43	14.96			15.33
Resistance 2 (R2)	14.96	14.66		15.00	15.27
Resistance 1 (R1)	14.66	14.48	14.81	14.76	15.20
Pivot Point	14.19	14.19	14.26	14.23	14.19
Support 1 (S1)	13.89	13.89	14.04	13.99	13.54
Support 2 (S2)	13.42	13.71		13.46	13.47
Support 3 (S3)	13.12	13.42			13.41
Support 4 (S4)					13.22